Guggenheim Issues Pessimistic Forecast for Immunome (NASDAQ:IMNM) Stock Price

Immunome (NASDAQ:IMNM) had its price objective decreased by Guggenheim from $35.00 to $25.00 in a research note released on Thursday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Lifesci Capital began coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Monday, March 10th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Price Performance

IMNM opened at $8.66 on Thursday. The business has a 50 day simple moving average of $9.80 and a 200-day simple moving average of $11.62. The stock has a market capitalization of $690.87 million, a P/E ratio of -1.07 and a beta of 1.93. Immunome has a 12 month low of $8.30 and a 12 month high of $26.70.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Research analysts anticipate that Immunome will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after acquiring an additional 1,520 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock valued at $202,000 after purchasing an additional 2,000 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock valued at $441,000 after purchasing an additional 2,005 shares during the period. Intech Investment Management LLC grew its position in shares of Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock valued at $201,000 after purchasing an additional 3,974 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after purchasing an additional 4,874 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.